FDMT 4D Molecular Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why FDMT matters now
4D Molecular Therapeutics, Inc. (FDMT) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.31 with -4.50% on the session and $643.5M in market capitalization; recent performance reads 1-month +15.00% and YTD +28.80%.
The latest financial table shown here is Q1 2026, with revenue of $3.0M, net income of $-68.8M, and EPS of $-1.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.8%.
The latest indexable market news headline is "4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $33.00; recent insider activity includes Chacko Jacob filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.46
P/S
5.72
EV/EBITDA
-2.77
DCF Value
$-10.93
FCF Yield
-25.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-12.4%
Operating Margin
-203.5%
Net Margin
-182.3%
ROE
-36.8%
ROA
-31.4%
ROIC
-37.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0M | $-68.8M | $-1.01 |
| Q4 2025 | $85.1M | $19.4M | $0.34 |
| FY 2025 | $85.2M | $-140.1M | $-2.42 |
| Q3 2025 | $90.0K | $-56.9M | $-1.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.00
Target (Median)
$33.00
Target Range
$33.00 - $33.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.76
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.